参考文献/References:
[1] Montalescot G,Sechtem U,Achenbach S,et al. 2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J,2013,34(38):2949-3003.
[2] 张运,陈韵岱,傅向华,等. 冠状动脉微血管疾病诊断和治疗的中国专家共识[J]. 中国循环杂志,2017,32(5):421-430.
[3] Ong P,Camici PG,Beltrame JF,et al. International standardization of diagnostic criteria for microvascular angina[J]. Int J Cardiol,2018,250:16-20.
[4] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.
[5] Del Buono MG,Montone RA,Camilli M,et al. Coronary microvascular dysfunction across the spectrum of cardiovascular?diseases:JACC?state-of-the-art review[J]. J Am Coll Cardiol,2021,78(13):1352-1371.
[6] Fearon WF,Kobayashi Y. Invasive assessment of the coronary microvasculature:the index of microcirculatory resistance[J]. Circ Cardiovasc Interv,2017,10(12):e005361.
[7] Kobayashi Y,Fearon WF. Invasive coronary microcirculation assessment—Current status of index of microcirculatory resistance[J]. Circ J,2014,78(5):1021-1028.
[8] Groepenhoff F,Klaassen RGM,Valstar GB,et al. Evaluation of non-invasive imaging parameters in coronary microvascular disease:a systematic review[J]. BMC Med Imaging,2021,21(1):5.
[9] Kelshiker MA,Seligman H,Howard JP,et al. Coronary flow reserve and cardiovascular outcomes:a systematic review and meta-analysis[J]. Eur Heart J,2022,43(16):1582-1593.
[10] Baller D,Notohamiprodjo G,Gleichmann U,et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis[J]. Circulation,1999,99(22):2871-2875.
[11] Naoumova RP,Kindler H,Leccisotti L,et al. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia:a randomized,double-blind,placebo-controlled study[J]. J Am Coll Cardiol,2007,50(21):2051-2058.
[12] Neglia D,Fommei E,Varela-Carver A,et al. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension[J]. J Hypertens,2011,29(2):364-372.
[13] Hachamovitch R,Rozanski A,Shaw LJ,et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy[J]. Eur Heart J,2011,32(8):1012-1024.
[14] van de Hoef TP,Lee JM,Boerhout C,et al. Combined assessment of FFR and CFR for decision making in coronary revascularization:from the multicenter international ILIAS registry[J]. JACC Cardiovasc Interv,2022,15(10):1047-1056.
[15] Monroy-Gonzalez AG,Tio RA,de Groot JC,et al. Long-term prognostic value of quantitative myocardial perfusion in patients with chest pain and normal coronary arteries[J]. J Nucl Cardiol,2019,26(6):1844-1852.
[16] Murthy VL,Naya M,Foster CR,et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve[J]. Circulation,2011,124(20):2215-2224.
[17] Murthy VL,Naya M,Foster CR,et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus[J]. Circulation,2012,126(15):1858-1868.
[18] Taqueti VR,Shaw LJ,Cook NR,et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve,not obstructive disease[J]. Circulation,2017,135(6):566-577.
[19] Murthy VL,Naya M,Taqueti VR,et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes[J]. Circulation,2014,129(24):2518-2527.
[20] Fukushima K,Javadi MS,Higuchi T,et al. Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease:a quantitative analysis of clinical 82Rb PET/CT studies[J]. J Nucl Med,2012,53(6):887-893.
[21] Shah NR,Charytan DM,Murthy VL,et al. Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD[J]. J Am Soc Nephrol,2016,27(6):1823-1829.
[22] Murthy VL,Naya M,Foster CR,et al. Coronary vascular dysfunction and prognosis in patients with chronic kidney disease[J]. JACC Cardiovasc Imaging,2012,5(10):1025-1034.
[23] Cecchi F,Olivotto I,Gistri R,et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,349(11):1027-1035.
[24] Feola M,Chauvie S,Rosso GL,et al. Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy:a myocardial PET study[J]. J Nucl Cardiol,2008,15(6):811-817.
[25] Dorbala S,Vangala D,Bruyere JJ,et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis[J]. JACC Heart Fail,2014,2(4):358-367.
[26] Gould KL,Kitkungvan D,Johnson NP,et al. Mortality prediction by quantitative PET perfusion expressed as coronary flow capacity with and without revascularization[J]. JACC Cardiovasc Imaging,2021,14(5):1020-1034.
[27] Rajappan K,Rimoldi OE,Dutka DP,et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries[J]. Circulation,2002,105(4):470-476.
[28] Alexánderson E,Ochoa JM,Calleja R,et al. Endothelial dysfunction in systemic lupus erythematosus:evaluation with 13N-ammonia PET[J]. J Nucl Med,2010,51(12):1927-1931.
[29] Recio-Mayoral A,Mason JC,Kaski JC,et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease[J]. Eur heart J,2009,30(15):1837-1843.
[30] Liao KP,Huang J,He Z,et al. Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all-cause mortality[J]. Arthritis Care Res(Hoboken),2021,73(2):159-165.
[31] Saghari M,Assadi M,Eftekhari M,et al. Frequency and severity of myocardial perfusion abnormalities using Tc-99m MIBI SPECT in cardiac syndrome X[J]. BMC Nucl Med,2006,6:1.
[32] Karpova IE,Samo?lenko LE,Soboleva GN,et al. Adenosine triphosphate stress (99m)Tc-MIBI single-photon emission computed tomography in the diagnosis Miocardial Iscemia in patients with Microvascular Angina[J]. Kardiologiia,2014,54(7):4-8.
[33] Fragasso G,Lauretta L,Busnardo E,et al. Prognostic role of stress/rest myocardial perfusion scintigraphy in patients with cardiac syndrome x[J]. Int J Cardiol,2014,173(3):467-471.
[34] 袁建伟,冯彦林,张培培,等. SPECT/CT心肌灌注显像在原发性微血管性心绞痛患者中的临床价值[J]. 广东医学,2016,37(6):841-844.
[35] Shrestha U,Sciammarella M,Alhassen F,et al. Measurement of absolute myocardial blood flow in humans using dynamic cardiac SPECT and 99mTc-tetrofosmin:method and validation[J]. J Nucl Cardiol,2015,24(1):268-277.
[36] Hsu B,Hu LH,Yang BH,et al. SPECT myocardial blood flow quantitation toward clinical use:a comparative study with 13N-Ammonia PET myocardial blood flow quantitation[J]. Eur J Nucl Med Mol Imaging,2017,44(1):117-128.
[37] Agostini D,Roule V,Nganoa C,et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera:head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study[J]. Eur J Nucl Med Mol Imaging,2018,45(7):1079-1090.
[38] Tsuda N,Shiraishi S,Sakamoto F,et al. Quantification of myocardial perfusion reserve using dynamic SPECT images of patients with chronic kidney disease[J]. J Cardiol,2018,71(2):174-180.
[39] Khaing T,Raymond CCW,Chan WX,et al. Quantification of myocardial blood flow and myocardial flow reserve with SPECT imaging technique[J]. J Nucl Cardiol,2018,26(1):318-323.